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Background: Type 2 diabetes mellitus (T2DM) is a chronic incurable disease associated with multi-systemic
complications. The chronic complications related to T2DM induce growing burden to the national health system.
Diabetic retinopathy (DR) is the most serious ocular complication associated with T2DM and one of the leading causes
of secondary blindness. The association between insulin use and DR risk has also been reported in different studies.
Methods: In order to obtain more informative results on the relationship between insulin intake and risk of
DR and to take into account more recent evidence, we conducted this meta-analysis by including all available
relevant cohort studies. A systemic literature search was performed via electronic databases inclu-apding Pubmed
and EMBASE to identify all available relevant studies until February 2014. A total of seven cohort studies were included
in this meta-analysis. In this meta-analysis, we conducted a rigorous search of all available published cohort studies to
quantify the possible association between insulin use and incidental DR in individuals with type 2 diabetes.
Results: Although major heterogeneity existed in this study, the significant association between insulin use and risk
of DR was detected. The subgroup analyses by study design, region, data source and adjustment of HbA1c generated
similar results. Also, when the DM duration was adjusted, no result was reported with significant difference.
Conclusion: The results of this meta-analysis helps to better explore the role of insulin use in DR risk development.
Meanwhile, our results are statistically robust and yield important conclusions. The underlying mechanism by
which insulin use increases DR risk should be explored in future in vitro and in vivo studies. Additional large-scale,
well-designed studies with sufficient data are needed to confirm our findings.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
2003724731291657
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Type 2 diabetes mellitus (T2DM) is a chronic incurable
disease associated with multi-systemic complications. It
is also a significant and growing source of morbidity and
mortality in the whole world [1,2]. The prevalence of
T2DM has rapidly increased in the past decades world-
wide, particularly in developing countries where people
are most vulnerable in confronting this complex and* Correspondence: wangfangzhuren@163.com
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unless otherwise stated.serious disease. Nowadays, increasing concern has been
attracted on T2DM because of the serious consequences
caused by both the disease itself and its complications.
For instance, chronic complications related to T2DM
not only induce growing burden to the national health
system and increasing rate of diabetes-related disability,
but also result in untimely mortality as well as lowered
life quality. Diabetic retinopathy is the most serious
ocular complication associated with T2DM and one of the
leading causes of secondary blindness [3]. The prevalence
of DR is reported to be ranging from 15.3% to 42.4%
in different epidemiologic studies. Different risk factors
of DR have been investigated and reported. Previoustd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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glucose, blood pressure, serum lipids, and smoking)
and non-modifiable risk factors (duration, age, genetic
predisposition, and ethnicity) are responsible for DR
progression [4-6].
Insulin is one of the most important therapeutic mea-
sures in the treatment of DM. Recently, the use of insulin
has been reported to be associated with various diseases,
such as hypertension, limb ischemia and diverse types
of cancers [5-8]. For example, a prospective study was
conducted to investigate the association between insulin
use and colorectal cancer (CRC) risk [7]. The association
between insulin use and DR risk has also been reported
in different studies. In a cross-sectional, multi-centered,
hospital-based study, the results showed that there was
more prevalent non-proliferative diabetic retinopathy
(NPDR) and proliferative diabetic retinopathy (PDR) in
insulin-taking than those in non-insulin-taking groups
[8]. Admittedly, each cross-sectional study design would
induce certain bias and limitations, thus weakening its
reliability. In order to obtain more informative and reliable
results on the relationship between insulin intake and risk
of DR and to take into account more recent evidence, we
conducted this meta-analysis by including all the available
relevant cohort studies [9].
Methods
Search strategy
We conducted the present meta-analysis following the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [10] and meta-analysis
of observation studies in epidemiology (MOOSE) guide-
lines [11]. A systemic literature search was performed via
electronic databases including Pubmed and EMBASE to
identify all available relevant studies until February 2014.
Manual retrieval of reference lists from retrieved articles
and reviews was also conducted. Medical subject heading
terms and key words used in the search included
“hypoglycemic agents”, “insulin” combined with “diabetic
retinopathy”. No language or other restrictions were set
in this study.
Study selection
Two authors (CZ and WFW) independently reviewed the
title and abstract of each study identified in the primary
searching process and excluded the studies that did not
answer the research question of interest. The full texts
of the remaining articles, including the references, were
carefully examined to determine whether relevant infor-
mation did exist inside. Disagreement between the two
reviewers was settled by discussing with the third reviewer
(FW). Studies were selected if they met the following
criteria: (1) a cohort study design was obtained; (2) the
association between insulin use and DR risk was reported;(3) Studies reporting different measures of RR like risk
ratio, rate ratio, hazard ratio (HR), and odds ratio (OR)
were reported.
Data extraction
The data extraction was conducted by two researchers
(CZ and WFW) independently and the following data was
extracted from each included study: the first author’s last
name, year of publication, geographic location(s), number
of all the enrolled subjects and cases, study design,
data source, duration of follow-up in cohort studies,
confounders for adjustment, and effect size estimates with
corresponding 95% CIs of all the enrolled papers. In stu-
dies where more than one estimate of effect was reported,
we chose the ‘most adjusted’ estimate in this study.
Methodological quality assessment
We used Newcastle-Ottawa Scale (NOS) to assess the
methodological quality of the enrolled cohort studies.
The NOS contains eight items that are classified into
three categories: selection (four items, one star each),
comparability (one item, up to two stars), and outcome
(three items, one star each). A “star” presents a “high-
quality” choice of individual study. Two reviewers (CZ and
WFW) assessed the methodological quality independently.
Disagreement between the two reviewers was settled by
discussing with the third reviewer (FW).
Statistical methods
We used the method of a random-effect model to calculate
summary RR and 95% CIs for assessing the association
between insulin use and risk of DR. The square of the
SEM was used as the estimated variance of the logarithm
of the OR. Only a random-effect model was assessed,
regardless of the significance of the heterogeneity. He-
terogeneity was assessed using the χ2 and I2 statistics. For
the χ2 statistic, a P value < 0.10 was considered statistically
significant for heterogeneity; for the I2 statistic, he-
terogeneity was interpreted as absent (I2: 0%–25%),
low (I2: 25.1%–50%), moderate (I2: 50.1%–75%), or
high (I2: 75.1%–100%), respectively. The subgroup analyses
were performed according to the following indexes inclu-
ding study design (prospective cohort or retrospective
cohort), data source (population based or hospital based),
study population (Europe, America and Asian), and control
for confounding factors. All statistical analyses were
performed using STATA, version 12.0 (STATA, College




A total of 5261 unique studies were yielded using the
previously mentioned search strategy in Medline and
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129 additional studies were identified from the references
of the retrieved articles (Figure 1). In all, 4905 articles
were found not to be involved in the association between
insulin intake and DR risk. From the 485 studies that
have been evaluated carefully, 416 reviews, case reports
and overlapped articles were further excluded. Out of
69 articles that examined the association between insu-
lin use and DR risk, 12 studies were excluded because
of not being cohort design-based studies, 44 studies
were excluded because of no data available in usable
format, and 6 studies were excluded because of the
mixture of T1DM and T2DM. As a result, a total of
seven cohort studies were finally included in this meta-
analysis [12-18].Characteristics of studies included in the meta-analysis
The characteristics of these studies included in this meta-
analysis are shown in Table 1. Among all the studies, a
total of 1711 cases including 19107 subjects were
identified. The earliest study was launched in 1967,
and the latest ended in 2010. Six of these studies were
population-based studies, and the remainder one study was
a hospital-based study. Among all the studies, 5 studies
were conducted in Europe, 1 in America and 1 in Asia. The
records of all the studies included both male and female
cases. The confounders for adjustments of each study were
presented in Table 1.Figure 1 Flow diagram of screened, excluded, and analyzed publicatiQuality of included studies
To evaluate the methodological qualities of the included
studies, the Newcastle-Ottawa quality tool was used in
the current meta-analysis. The Newcastle-Ottawa quality
assessment score of the most studies (mean: 6.86; stan-
dard deviation: 1.21) and all the studies were at a relatively
high level, indicating a high methodological quality of the
enrolled studies (Table 2).Quantitative synthesis
Figure 2 displayed the pooled associations between insulin
use and DR risk. The pooled result of all the 7 included
studies showed that insulin use is associated with increased
risk of DR (RR = 2.30, 95% CI, 1.35-3.93). Table 3 displayed
the effects of insulin use and DR risk in subgroup analysis
by adjusting confounding factors including status, study
type, country, and study designs. In both prospective
studies (RR, 2.38; 95% CI, 1.28-4.41) and retrospective
studies (RR, 2.30; 95% CI, 1.11-3.43) subgroups, a sig-
nificant correlation between insulin use and incidence
rate of DR was observed. When subgroup analyses were
conducted according to the geographic locations, signifi-
cant associations were detected in Europe (RR, 1.85; 95%
CI, 1.12-3.08), Asia (RR, 3.43; 95% CI, 1.93-6.08) and
America (RR, 4.90; 95% CI, 2.63-5.79). Moreover, similar
results were yielded in the subgroup analyses by data
source (population based or hospital based), follow-up
duration (over 5 years or less than 5 years) and adjustmentsons.
Table 1 Characteristics of the study population included in this study
Study Year of publication Study design Data source Country All subjects DR cases Study period Sex Confounders for adjustment
Gunnlaugsdottir E 2012 Prospective Population based Iceland 4,995 138 1967-1997 M/F Age, sex, systolic BP. duration of DM,
oral hypoglycaemic, HbA1c, hypertension
and microlbuminuria
Geir Bertelsen 2012 Prospective Population based Norway 514 110 2007-2008 M/F Age, sex, systolic BP, oral hypoglycaemic,
HbA1c, hypertension and microlbuminuria,
BMI, glaucose
Schweitzer K 2009 Prospective Population based American 500 175 2004-2007 M/F NA
Romero-Aroca P 2007 Prospective Hospital based Spain 741 205 2005.1-2005.12 M/F NA
Hove MN 2004 Restropective Population based Denmark 10,851 378 2000.1-2000.12 M/F NA
Henricsson M 1996 Prospective Hospital based Sweden 1,378 438 1990-1995 M/F Age, sex and duration of diabetes
Deng Y 2014 Prospective Population based China 128 267 2009-2010 M/F Age of diabetic onset, duration of diabetes,
BMI, microalbuminuria,HbA1c, fasting plasma
glucose, creatinine















Table 2 Quality assessment of included studies1
Author Quality assessment criteria
Selection Comparability Outcome Overall quality
Gunnlaugsdottir E 2012 ** ** ** 6
Geir Bertelsen 2012 ** ** ** 6
Schweitzer K 2009 *** ** *** 8
Romero-Aroca P 2007 ** ** *** 7
Hove MN 2004 *** ** ** 7
Henricsson M 1996 ** ** ** 6
Deng Y 2014 *** ** *** 8
1the Newcastle-Ottawa Scale (NOS) was obtained to assess the methodological quality of the included studies.
**Two points; ***Three points.
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When DM duration was adjusted, no significant association
between insulin use and risk of DR was detected (RR, 2.18;
95% CI, 0.80-5.93).Heterogeneity and publication bias
A significant heterogeneity was observed when all the 7
cohort studies were included (I2, 89.3%; P < 0.001). In the
subgroup analyses, the heterogeneity remains significant.
However, when one study by Henricsson M et al. [16] was
excluded from the meta-analysis, (I2, 26.3%; P = 0.237),
only low heterogeneity was observed. The differences in
the data source or regional characteristics might be
responsible for generating a significant heterogeneity.
However, the heterogeneity remains significant when
that study was excluded (RR, 2.86; 95% CI, 2.28-3.58).Figure 2 Forest plot: overall meta-analysis of insulin use and DR risk.
the study-statistical weight, i.e. inverse of variance); horizontal lines indicate
estimate with its corresponding 95% confidence interval.No significant publication bias was found in the 7
enrolled studies (Begg’s test, P for bias = 0.30; Eegg’s
test, P for bias = 0.297).
Discussion
In this meta-analysis, we conducted a rigorous search
of all available published cohort studies to quantify the
possible association between insulin use and incidental
DR in individuals with type 2 diabetes. Although a dra-
matic heterogeneity existed in this study, the significant
association between insulin use and DR was detected. The
subgroup analyses by study design, region, data source
and adjustment of HbA1c yielded similar results. In the
group when the DM duration was adjusted, no significant
result was reported.
Insulin and DR risk have been discussed for long. Several
cross-sectional studies have reported that insulin use isSquares indicated study-specific risk estimates (size of square reflects
95% confidence intervals; diamond indicates summary relative risk
Table 3 Detailed outcomes on insulin use and RRs of DR
Subgroups No. of
studies
Pooled estimate Tests of heterogeneity
RR 95% CI P value I2 (%)
All subjects 7 2.30 1.35-3.93 < 0.001 89.3
Study design
Prospective study 6 2.38 1.28-4.41 < 0.001 90.9
Retrospective study 1 2.30 1.11-3.43 — —
Geographic location
Europe 5 1.85 1.12-3.08 < 0.001 80.4
Asia 1 3.43 1.93-6.08 — —
North America 1 4.90 2.63-5.79 — —
Data source
Population based 5 2.94 2.19-3.94 0.234 28.1
Hospital based 2 1.34 0.65-2.76 0.024 80.5
Follow-up duration
≥ 5 years 1 3.51 1.59-7.76 — —
< 5 years 6 2.17 1.22-3.85 < 0.001 90.3
Major confounders adjusted
DM duration
Yes 3 2.18 0.80-5.93 < 0.001 91.7
No 4 2.53 1.74-3.67 0.115 49.4
HbA1c
Yes 3 2.88 2.00-4.14 0.454 0
No 4 2.30 1.35-4.14 < 0.001 92.7
RR: relative risk; CI: confidence interval; DM: diabetes mellitus.
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the association between insulin use and risk of DR was
reported [15,16]. According to data from the Tromsø Eye
Study, a study including 514 participants with diabetes
aged from 46 to 87 years, showed that DR risk was associ-
ated with insulin use (OR 2.14, 95% CI 1.19-3.85) [17]. In
another cross-sectional study performed among 261 type
2 diabetic patients at Chandrubeksa Hospital on January
2011, the result demonstrated that the patients who had
received insulin treatment were more likely to suffer from
DR than those who had not (OR 3.95, 95% CI 1.86, 8.39)
[19]. However, considering that various potential sources
would be involved in cross-sectional study design, a cohort
study design would be preferred for yielding less potential
bias. Meta-analysis is now a useful statistical tool to pool
relevant studies together and gain a more powerful con-
clusion. The meta-analysis was also used in the search for
potential risk factors for DR. Zhang et al. reported that in
a meta-analysis including nine studies with 1, 217 cases
and 1, 459 controls, 4G/5G polymorphism in the PAI-1
gene potentially increased the risk of DR in type 2 diabetes
and showed a discrepancy between different ethnicities
[20]. In this study, we conducted a meta-analysis only
including cohort studies to investigate the associationbetween insulin use and risk of DR. The high methodo-
logical quality of included studies and powerful statistical
tool employed in this meta-analysis combinely supported
the reliability of the presented robust conclusion.
In the subgroup analyses, we found that the association
between insulin use and DR risk became non-significant
when the DM duration was adjusted. It suggested that the
increasing risk of DR in insulin users might be associated
with a longer DM duration, while DM duration was
generally accepted as a risk factor for DM [19,20]. In
the subgroup analyses by other confounding factors, no
different results were found. The underlying mechanism of
the association between insulin use and risk of DR should
be further explored in more studies. In our meta-analysis
with seven cohort studies included, we pointed that insulin
use might be a risk factor of DR. This finding pointed that
we should be more discreet in the patients with long time
insulin use history and the DR detection should be more
careful. Besides, as insulin use is reported to be risk factor
of different diseases [21,22], any inapposite insulin use in
the treatment of patients should be avoided.
Only cohort studies were enrolled in the present meta-
analysis, which helps to add strength to our study. Besides,
access to adequate literature and detailed analyses of the
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the correlation between insulin use and DR risk. However,
limitations of this meta-analysis should also be noted.
First, among all the included studies, not enough studies
provided the data of insulin use and NPDR or PDR risk,
which make it difficult to further explore the role of
insulin take in DR onset and progression. Second, consi-
dering that only seven cohort studies were included, the
power of the conclusion was relatively limited. The
third limitation is that most studies lack a long enough
follow-up duration and thus more studies are needed to
confirm our conclusion.
Conclusion
Despite these aforementioned limitations, the results of this
meta-analysis provide a more complete and systematic
picture of the role of insulin use in the development
DR risk. Meanwhile, our results are statistically robust
and yield important conclusions. The mechanisms by
which insulin use increases the DR risk should be further
explored in future in vitro and in vivo studies. Additional
large-scale, well-designed studies with sufficient data are
still wanted to confirm our conclusion.
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